Overview
Mermaid diagram (expand to render)
MK-1167 is an investigational drug developed by Merck Sharp & Dohme (MSD) in collaboration with the University of Kansas Alzheimer's Disease Research Center. The trial is a Phase 2 study evaluating MK-1167 as an adjunctive therapy for patients with mild to moderate Alzheimer's disease dementia. This trial represents Merck's continued investment in novel therapeutic approaches for Alzheimer's disease beyond the established amyloid-targeting and neurotransmitter-based strategies["@nct06721156"][@merckscience][@kumed].
Alzheimer's disease is the most common cause of dementia worldwide, affecting approximately 6.5 million Americans alone. The disease is characterized by progressive cognitive decline, with amyloid-beta plaque accumulation and tau neurofibrillary tangles serving as hallmark pathological features. Despite significant research investment, only limited disease-modifying therapies have received approval, highlighting the urgent need for novel therapeutic approaches that target different aspects of disease pathogenesis.
Trial Details
| Attribute | Value |
|-----------|-------|
| NCT Number | NCT06721156 |
| Phase | Phase 2 |
| Sponsor | Merck Sharp & Dohme (MSD) |
| Collaborator | University of Kansas Alzheimer's Disease Research Center |
| Status | Recruiting |
| Participants | 350 |
| Study Start Date | Expected 2025 |
| Estimated Completion | 2027 |
| Age Range | 50-85 years |
| Diagnosis | Mild to Moderate Alzheimer's Disease |
| Intervention | MK-1167 (dose to be determined) |
| Control | Placebo |
| Randomization | 1:1 |
| Duration | 52 weeks (1 year) |
Trial Population Characteristics
The trial targets patients with mild to moderate Alzheimer's disease dementia, representing a critical window for therapeutic intervention. Patients in this disease stage typically exhibit measurable cognitive impairment but retain significant functional capacity, making them ideal candidates for disease-modifying therapies that may slow progression.
Inclusion Criteria:
- Diagnosis of probable Alzheimer's disease per NIA-AA criteria[@niaaa]
- MMSE score between 12-26 (mild to moderate dementia)
- Stable on acetylcholinesterase inhibitor or memantine therapy (if using) for at least 12 weeks
- Age 50-85 years
- Able to provide informed consent or have capable legal representative
- Confirmed presence of amyloid pathology via PET scan or CSF biomarkers
Exclusion Criteria:
- Significant neurological disease other than AD
- Psychiatric disorder that could affect participation (e.g., major depression, schizophrenia)
- Significant medical comorbidities that would preclude study participation
- Use of investigational therapies within 30 days
- History of substance abuse within past year
Study Design
The trial employs a randomized, double-blind, placebo-controlled design, representing the gold standard for clinical efficacy assessment. Participants will be randomized to receive either MK-1167 at varying doses or placebo alongside standard of care therapy for Alzheimer's disease[@nct06721156].
Randomization and Blinding
The 1:1 randomization ensures equal distribution of patient characteristics between treatment and control arms. Double-blind design prevents bias from both investigators and participants knowing treatment assignment, ensuring objective assessment of outcomes. An independent data monitoring committee will conduct periodic safety reviews.
Treatment Arms
| Arm | Description |
|-----|-------------|
| Arm 1 | MK-1167 low dose + standard of care |
| Arm 2 | MK-1167 high dose + standard of care |
| Arm 3 | Placebo + standard of care |
Standard of care includes approved Alzheimer's medications such as donepezil, rivastigmine, galantamine, or memantine, either as monotherapy or combination therapy.
Mechanism of Action
The specific mechanism of MK-1167 has not been publicly disclosed. Merck has not revealed the molecular target or pathway being modulated. However, the development suggests a novel approach to Alzheimer's disease treatment beyond the established amyloid, tau, and neurotransmitter-based strategies.
Potential Mechanisms Under Investigation
Based on Merck's neuroscience pipeline and typical Phase 2 trial designs, several possibilities exist for MK-1167's mechanism:
Neuroinflammation Modulation:
The role of neuroinflammation in Alzheimer's disease pathogenesis has become increasingly recognized. Microglial activation, cytokine release, and inflammatory cascades contribute to neuronal damage. Novel anti-inflammatory approaches targeting specific inflammatory pathways may provide benefit beyond current therapies.
Synaptic Function Enhancement:
Synaptic loss correlates strongly with cognitive decline in Alzheimer's disease. Therapies that preserve or enhance synaptic function could potentially slow cognitive deterioration independent of amyloid or tau pathology.
Metabolic Support:
Brain energy metabolism is impaired in Alzheimer's disease. Interventions supporting neuronal metabolism, mitochondrial function, or glucose utilization may have therapeutic potential.
Proteostasis Restoration:
Dysregulated protein homeostasis contributes to amyloid and tau aggregation. Mechanisms promoting protein clearance or preventing aggregation represent active research areas.
Clinical Endpoints
Primary Endpoints
Cognitive Function:
- Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog-13)
- Change in Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)
- MMSE score changes
Functional Assessment:
- Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
- Functional Activities Questionnaire (FAQ)
Secondary Endpoints
Biomarker Outcomes:
- CSF amyloid-beta and tau levels
- Amyloid PET standardized uptake value ratio (SUVR)
- Tau PET imaging
Safety and Tolerability:
- Adverse event frequency and severity
- Discontinuation rates
- Laboratory parameter changes
- Electrocardiogram changes
Exploratory Outcomes:
- Neuroimaging volumetry
- Fluid biomarker panels
- Pharmacokinetic profiling
Clinical Rationale
The trial is based on emerging research suggesting novel therapeutic targets in Alzheimer's disease pathogenesis. The collaboration with the University of Kansas ADRC indicates a focus on translating basic science findings into clinical applications[@kumed].
Unmet Need in Alzheimer's Disease
Despite advances in understanding Alzheimer's disease biology, significant gaps remain in therapeutic options:
Limited Disease-Modifying Options: Current approved therapies primarily provide symptomatic relief without substantially altering disease progression.
Heterogeneous Patient Responses: Patients respond variably to existing treatments, suggesting diverse underlying pathophysiology.
Need for Combination Approaches: Adjunctive therapies targeting multiple pathways may provide additive benefits.
Biomarker-Driven Selection: Improved patient selection through biomarkers may enhance trial success rates.Merck's Neuroscience Portfolio
Merck has maintained a significant neuroscience research program, with previous contributions to Alzheimer's disease therapeutics. Their pipeline includes multiple candidates targeting different aspects of disease pathogenesis[@merckscience].
Trial Sites
The trial is being conducted at multiple sites across the United States. Specific site locations will be listed on ClinicalTrials.gov when fully operational.
Participating Institutions
- University of Kansas Alzheimer's Disease Research Center (lead site)
- Major academic medical centers with memory disorders programs
- Specialized clinical research organizations
Regulatory Context
This trial operates under FDA oversight through the Investigational New Drug (IND) application process. The trial design aligns with FDA guidance for Alzheimer's disease drug development, incorporating:
- amyloid confirmation requirement
- validated cognitive endpoints
- biomarker substudies
- long-term follow-up considerations
Scientific Significance
The MK-1167 trial represents several important aspects of contemporary Alzheimer's disease research:
Novel Mechanism Exploration
By pursuing a mechanism distinct from amyloid-targeting antibodies (lecanemab, donanemab) or tau-targeting therapies, MK-1167 contributes to understanding whether alternative pathways can provide clinical benefit.
Adjunctive Therapy Paradigm
Evaluating MK-1167 as add-on to standard care reflects real-world treatment approaches where patients typically receive combination therapy.
Precision Medicine Approach
The use of biomarker confirmation (amyloid positivity) ensures enrolled patients have confirmed Alzheimer's pathology, potentially improving signal detection.
Risk and Considerations
Potential Benefits
- Novel mechanism with potential for disease modification
- Adjunctive design may provide additive benefit to standard care
- Participation contributes to Alzheimer's disease research
Potential Risks
- Unknown efficacy (Phase 2)
- Potential for adverse effects
- Time commitment (52 weeks)
- Site visits and assessments
Mitigation
- Close safety monitoring
- Independent data monitoring committee
- Standard of care maintained throughout
This trial joins numerous ongoing Phase 2 Alzheimer's disease studies:
- [LHP588 Phase 2 P. gingivalis trial](/clinical-trials/lhp588-phase2-p-gingivalis-nct06847321)
- [E2814 4R Tau Phase 2](/clinical-trials/e2814-4r-tauopathy-phase-2-nct05615614)
- [AL002 TREM2 Agonist](/clinical-trials/al002-trem2-agonist-alzheimers)
- [KI scale expansions]
References
[MK-1167 Adjunctive Therapy in Mild to Moderate Alzheimer's Disease (NCT06721156)](https://clinicaltrials.gov/study/NCT06721156)
[Merck Neuroscience Research Pipeline](https://www.merck.com/research/neuroscience/)
[University of Kansas Alzheimer's Disease Research Center](https://kucenter4ad.org/)
[NIA-AA Criteria for Alzheimer's Disease](https://www.nia.nih.gov/research/dna/alzheimers-disease-nia-aa-criteria)Related Pages
- [Alzheimer's Disease Clinical Trials](/clinical-trials/alzheimers-disease-trials)
- [Merck Pharmaceuticals](/companies/merck-msd)
- [Phase 2 Clinical Trials](/clinical-trials/phase-2-trials)
- [Amyloid-Targeting Therapies](/mechanisms/amyloid-cascade)
- [Neuroinflammation in Alzheimer's](/mechanisms/neuroinflammation)
Alzheimer's Disease Treatment Landscape
Current Standard of Care
The current treatment paradigm for AD includes:
Symptomatic Treatments
- [Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine)](/genes/ace)
- [NMDA receptor antagonist (memantine)](/entities/nmda-receptor)
- [Combination therapy (donepezil + memantine)](/genes/th)
Disease-Modifying Therapies
- [Amyloid-targeting antibodies (lecanemab, donanemab)](/genes/ar)
- [Recently approved (2023-2024)](/proteins/app)
- [Significant controversy regarding benefit/risk](/genes/ar)
Unmet Medical Need
Despite recent approvals, significant unmet need remains:
- [Symptomatic treatments**: Modest efficacy, do not address disease](/treatments)progression
- Disease-modifying therapies: Associated with ARIA, limited to early disease
- Prevention: No approved therapies for pre-symptomatic stages
- Combination approaches: Not well explored in AD
Challenges in AD Drug Development
Historical Context
AD drug development has the highest failure rate of any disease area:
- 99% failure rate for disease-modifying therapies
- Over 200 failed clinical trials
- Multiple high-profile late-stage failures
Key Challenges
Biological complexity: Multiple pathways involved
Diagnostic uncertainty: Clinical diagnosis imperfect
Biomarker limitations: Need better patient selection
Trial duration: Long trials needed for meaningful endpoints
Heterogeneity: Multiple disease subtypesMerck's Neuroscience Pipeline
Historical Context
Merck has a long history in neuroscience drug development:
- Previous successes: Petolerant, Rebif, etc.
- Lecanemab development: Originally by Biogen, Merck involved in earlier work
- Current focus: Novel mechanisms beyond amyloid
MK-1167 Development
While the specific mechanism is undisclosed, several possibilities:
Novel neurotransmitter targets
- Modulation of glutamate or GABA signaling
- Non-NMDA receptor approaches
Anti-inflammatory approaches
- Microglial modulation
- Peripheral immune system effects
Metabolic approaches
- Mitochondrial function
- Energy metabolism modulation
Synaptic plasticity enhancers
- AMPA receptor modulators
- Dendritic spine stabilization
Industry Trends
Merck represents a larger trend:
- Beyond amyloid: Focus on complementary mechanisms
- Academic partnerships: Leveraging university research
- Precision medicine: Biomarker-driven approaches
Clinical Trial Design Considerations
Phase 2 Trial Architecture
Dose-Finding Components
- Multiple dose cohorts
- Randomized, placebo-controlled
- Dose-escalation or parallel design
Patient Population Selection
- Mild to moderate disease: Most common for Phase 2
- Biomarker confirmation: Increasingly important
- Exclusion criteria: Manage comorbidities
Outcome Measures
Primary Endpoints
- Cognitive measures: ADAS-Cog, MMSE, CDR
- Clinical global: CIBIC+, CGI-C
- Functional: ADL, FAQ
Secondary Endpoints
- Biomarkers: CSF, imaging
- Brain volumes: MRI measures
- Quality of life: QoL-AD
- Biomarker targets: Target engagement
Statistical Considerations
- Sample size: 350 is moderate for Phase 2
- Duration: 2-year timeline suggests meaningful endpoints
- Power: Designed to detect moderate effects
Future of AD Therapeutics
Emerging Approaches
Novel Mechanisms in Development
Tau-targeted therapies
- Anti-tau antibodies
- Small molecule inhibitors
- Tau aggregation inhibitors
Neuroprotection
- Mitochondrial protectors
- Antioxidants
- Neurotrophic factors
Immune modulation
- Microglial modulators
- Peripheral immune approaches
- TREM2 targeting
Metabolic interventions
- GLP-1 analogs
- Metabolic enhancers
Precision Medicine in AD
The field is moving toward:
- Biomarker-driven selection: Amyloid-positive, tau-positive
- Genetic subtypes: APOE, other genetic variants
- Endophenotypes: Different biological subtypes
- Combination therapies: Multi-target approaches
Regulatory Landscape
Recent Approvals
- Lecamab (Leqembi): Accelerated approval, full approval
- Donanemab (Kisunla): Conditional approval
- Aduhelm: Withdrawn from market
Implications for MK-1167
- Regulatory flexibility: More open to novel mechanisms
- Endpoint evolution: Accepting biomarker endpoints
- Conditional approval: Possible with limited efficacy
Strategic Considerations
Why Adjunctive Therapy?
The adjunctive approach makes sense because:
- Standard of care: Builds on existing treatments
- Regulatory path: Clear comparators
- Patient population: Larger pool than monotherapy
- Commercial potential: Multiple options for patients
Collaboration with Academic Centers
University of Kansas ADRC partnership suggests:
- Academic expertise: Clinical trial infrastructure
- Biomarker capabilities: Advanced diagnostics
- Patient access: Regional recruitment
- Scientific input: Mechanistic guidance
Timeline Analysis
- Start 2025: Expected recruitment timeline
- Completion 2027: 2-year treatment + follow-up
- Potential filing: 2028-2029 if successful
Summary
The MK-1167 trial represents:
- Novel mechanism: Merck's approach beyond amyloid
- Phase 2 design: Standard for mid-stage development
- Adjunctive approach: Building on existing therapies
- Academic collaboration: Leveraging university expertise
- Timeline: 2-year study with 350 participants
The trial adds to the growing AD pipeline and represents continued pharmaceutical industry investment in Alzheimer's disease therapeutics despite the field's challenges.
Pathway Diagram
The following diagram shows the key molecular relationships involving MK-1167 Phase 2 Alzheimer's Disease Trial discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)